AI and automation integration halves the time and cost of new drug development [Korean]

Author: 김윤화 기자 Kyh94 | Source: 비즈니스워치 | Read the full article in Korean

In a groundbreaking development, Insilico Medicine, a company based in the U.S. and Hong Kong, is revolutionizing the field of drug development by integrating artificial intelligence (AI) and automation. Their innovative approach has reportedly halved the time and costs typically associated with creating new medications. The company has made headlines for its successful use of generative AI in drug discovery, including the recent clinical trials of a drug called "Rentosein," which has shown promising results in treating a specific lung disease.

Alex Zhavoronkov, the CEO of Insilico Medicine, highlighted the company's achievements, including the development of over 30 drug candidates, with 10 already receiving approval for clinical trials. The company has partnered with several South Korean pharmaceutical firms to enhance its research capabilities. Zhavoronkov is set to speak at the upcoming Bio Korea 2025 event, where he will discuss the potential of AI in drug development and the future of healthcare.

Insilico Medicine's AI platform, known as "Pharma.AI," is designed to streamline the entire drug development process, from initial design to clinical trials. This technology not only accelerates the discovery of new drugs but also improves their effectiveness and safety. Zhavoronkov's ultimate goal is to leverage AI to tackle not just diseases but also the aging process itself, showcasing the vast potential of AI in transforming healthcare.

[Read More (translated)]